Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis  by Condeelis, John & Pollard, Jeffrey W.
Leading Edge
Minireview
Cell 124, January 27, 2006 ©2006 Elsevier Inc. 263
In their landmark review, Hanahan and Weinberg (2000) 
enumerated six traits that cells require for malignant growth. 
These are self-sufficiency from external growth signals, 
insensitivity to negative growth signals, resistance to apop-
tosis, limitless replicative potential, sustained angiogenesis, 
and acquisition of tissue invasiveness. Although the last two 
traits depend on heterotypic interactions with nonmalignant 
cells, the review’s emphasis was clearly upon intrinsic genetic 
changes in tumor cells. Despite considerable success in 
the molecular definition of these changes, it has become 
apparent that tumors are complex ecologies of different 
cell types and that the full manifestation of the malignant 
potential of transformed epithelial cells requires an appropri-
ate support structure from the stroma. The stroma is com-
plex and changing and depends on the tumor’s origin. It can 
consist of resident fibroblasts, adipocytes, and blood and 
lymph vessels and may also be infiltrated by a wide range of 
hematopoietic cells. Recent studies have shown that all of 
these cell types can influence tumor progression to varying 
degrees depending on tumor type.
Hematopoietic cells are recruited to most tumors, and 
one group, the tumor-associated macrophages, can consti-
tute a large portion of the tumor mass (Pollard, 2004). Two 
strands of evidence derived from clinical and epidemiologi-
cal studies implicate these macrophages in cancer. First is 
the association of chronic inflammation, which involves 
macrophages, with cancer initiation and promotion and the 
reduction of cancer risk by treatment with anti-inflammatory 
drugs (Balkwill et al., 2005). Second, a high density of these 
tumor-associated macrophages correlates with poor prog-
nosis in over 80% of studies published (Bingle et al., 2002).
Macrophages appear to be directly involved in tumor 
progression and metastasis. Removal of macrophages in 
mice—through a homozygous null mutation of the gene that 
encodes the macrophage growth factor, colony-stimulating 
factor-1 (CSF-1)—reduced the rate of tumor progression and 
almost completely ablated the metastasis of the tumor in a 
mouse model of breast cancer (induced by expression of the 
polyoma middle T oncoprotein in mammary epithelial cells). 
In contrast, overexpression of CSF-1 accelerated tumor 
progression and metastasis in this mouse model (Lin et al., 
2001). Blocking expression of mouse CSF-1 in a xenograft 
model (mice engrafted with human tumor cells) reduced 
the growth and metastatic capacity of the tumor cells, and 
this was associated with reduced invasion of host-tumor-
associated macrophages (Pollard, 2004 and references 
within). These data suggest that a causal relationship exists 
between poor prognosis in a variety of reproductive tumors 
and overexpression of CSF-1, which recruits macrophages. 
Indeed, in human breast cancers, there is a positive correla-
tion between poor prognosis and the density of tumor-asso-
ciated macrophages (Lin et al., 2002). Furthermore, recent 
experiments using specific ablation of a key player in the 
inflammatory response, NF-κB, in tumor-associated macro-
phages showed that this signaling pathway is important for 
tumor initiation and growth (Karin and Greten, 2005). Clinical 
and experimental evidence therefore links tumor-associated 
macrophages with tumor progression and metastasis.
Macrophages can provide support for developing tis-
sues through their matrix remodeling capacities, synthesis 
of growth and angiogenesis factors, and their engulfment 
of apoptotic cells. Excellent examples of these functions 
are displayed by the macrophage-derived osteoclasts that 
remodel bone and for macrophages in mammary develop-
ment (Figure 1) (Lin et al., 2002). During wound healing, mac-
rophages are sentinel cells that organize immune defenses 
and coordinate the tissue repair process, which involves 
epithelial migration, matrix remodeling, and angiogenesis 
(Coussens and Werb, 2002). We argue here that tumors 
recruit macrophages and create a microenvironment that 
causes macrophages to suppress immune functions and 
instead adopt trophic roles found during development and 
repair (Figure 1). However, in contrast to normal tissue, tumor 
cells have lost their “off switches” due to intrinsic mutations
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Macrophages within the tumor microenvironment facilitate angiogenesis and extracellular-
matrix breakdown and remodeling and promote tumor cell motility. Recent studies reveal that 
direct communication between macrophages and tumor cells leads to invasion and egress 
of tumor cells into the blood vessels (intravasation). Thus, macrophages are at the center of 
the invasion microenvironment and are an important drug target for cancer therapy.
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and no longer respond to positional information. Therefore, 
they continue to grow, invade the surrounding tissue, and 
escape to distant sites. Here, we propose six extrinsic traits 
conferred by macrophages that enhance tumor incidence, 
progression, and metastasis. These are chronic inflamma-
tion, matrix remodeling, tumor cell invasion, intravasation, 
angiogenesis, and seeding at distant sites (Figure 2).
Inflammation
Infections that cause chronic inflammation are responsible 
for >15% of cancers worldwide (Coussens and Werb, 2002). 
Among the best documented of these are the causal rela-
tionships between the bacterium Helicobacter pylori and 
stomach cancer and between the helminth worm Schis-
tosoma hematobium and bladder cancer. Furthermore, 
compounds such as asbestos and cigarette smoke cause 
a chronic inflammatory state that promotes tumorigen-
esis. Additionally, there are strong associations between 
increased cancer risk and genetic conditions that cause 
continuous inflammatory disorders such as Crohn’s disease; 
conversely, there is a reduction in cancer risk with the use 
of nonsteroidal anti-inflammatory drugs. In cases of chronic 
inflammation, the persistent recruitment of immune cells is 
thought to establish a microenvironment that is mutagenic 
through the production of reactive oxygen and nitrogen spe-
cies that can initiate malignant changes in nearby epithelial 
cells. Furthermore, this microenvironment is rich in growth 
factors and cytokines that can stimulate proliferation and 
survival of the mutated premalignant cells, enabling them to 
accumulate further genetic changes on the path to becom-
ing frank malignancies. The role of inflammation in cancer 
initiation and promotion has been recently reviewed (Balkwill 
et al., 2005; Coussens and Werb, 2002; Pollard, 2004).
Matrix Remodeling, Tumor Cell Invasion, and 
Intravasation
In the early stages of tumorigenesis, macrophages are 
found at points of basement-membrane breakdown during 
the transition to malignancy and at the invasive front of more 
advanced tumors. This suggests that tumors exploit the nor-
mal matrix remodeling capacities (Figure 1) of macrophages, 
enabling them to egress into and migrate through the sur-
rounding stroma (Lin et al., 2002, Pollard, 2004, Wyckoff et 
al., 2004). Multiphoton imaging has revealed remarkable 
interactions between tumor cells, macrophages, and blood 
vessels, supporting the notion that macrophages enhance 
tumor cell migration and invasion (Condeelis and Segall, 
2003). Additionally, macrophages are found throughout 
mammary tumors and in association with blood vessels. In 
Figure 1. Tumor Cells Co-opt Macrophage Functions
Macrophages aid in the invasion of epithelial cells during morphogenesis 
(left) and are co-opted by tumor cells during metastasis (right). Multi-
photon image at the bottom left: epithelial cells (blue) of a terminal end 
bud in a mouse mammary gland during normal glandular development. 
The bud is surrounded by macrophages (red) that precede the invasion 
of the fat pad by the epithelial cells. Multiphoton image at the bottom 
right: tumor-associated macrophages (red) and tumor cells (green) at an 
invasive edge in a mouse mammary tumor. Adapted from Wyckoff et al. 
(2004) and Lin et al. (2002).
Figure 2. Six Traits for Malignancy Promoted by Macrophages
Tumors direct macrophages to adopt a trophic role that facilitates six 
traits that are extrinsic to the intrinsic genetic changes of tumor cells. The 
wheel (in deference to Hanahan and Weinberg, 2000) can turn in either 
direction, allowing macrophages to contribute to invasion, intravasation, 
angiogenesis, and extravasation equally. The image in the center is a 
multiphoton micrograph of a mammary tumor (green) and associated 
macrophages (red) in a living mouse.
Cell 124, January 27, 2006 ©2006 Elsevier Inc. 265
mammary carcinomas derived from implanted tumor cells 
and in tumors induced by expression of polyoma middle 
T oncogene in mouse mammary epithelium, tumor cells 
migrate toward blood vessels, suggesting a chemotactic 
stimulus originating from blood vessels. Invasive tumor cells 
and macrophages within primary mammary tumors of rats 
and mice have been found to migrate together, but only in 
response to EGF and CSF-1 (Wang et al., 2005). Inhibition 
of either CSF-1 or EGF receptor signaling blocks migration 
of both cell types in vivo. The expression patterns of these 
receptors and their ligands in tumor cells and macrophages 
(Condeelis et al., 2005) and experiments demonstrating that 
tumor cells and macrophages migrate toward each other 
and together penetrate a dense collagen matrix suggest the 
existence of an EGF/CSF-1 paracrine signaling loop. A key 
observation is that the stimulation of tumor cells by EGF and 
macrophages by CSF-1 induces invadopod and podosome 
formation, respectively. Thus, each cell type is endowed 
with exaggerated extracellular-matrix remodeling activity 
and invasive properties at the same time that their migratory 
activity increases (Yamaguchi et al., 2006) (Figure 3).
Macrophages also enhance the ability of tumor cells to 
enter blood vessels (intravasation). Importantly, intravasation 
efficiency is directly correlated with the migration of tumor 
cells toward blood vessels and with macrophage density 
in the primary tumor. Furthermore intravasation can be 
blocked by pharmacologic inhibition of EGFR signaling. This 
suggests that the paracrine loop, via CSF-1 and EGF recep-
tor signaling in macrophages and tumor cells, respectively, 
is operating during intravasation (Wyckoff et al., 2004).
These data show that macrophages control tumor 
intravasation, and this is one explanation for the inhibition 
of metastasis when macrophages are ablated from experi-
mental tumor models (Lin et al., 2002). These data are also 
consistent with correlative clinical data in breast cancer 
showing that overexpression of CSF-1 in tumor cells and 
EGF in macrophages are both independent predictors of 
poor prognosis (Lin et al., 2002; Leek and Harris, 2002). 
These results directly implicate macrophages in the induc-
tion of tumor cell migration, invasion, and intravasation in the 
primary tumor (Figure 3).
Gene-expression profiling of mammary tumor cells that 
migrate with macrophages indicates that macrophages may 
help to elicit a particular “invasion signature” of gene expres-
sion in these tumor cells. This identifies the tumor cells as 
neither proliferating nor apoptotic, but they have heightened 
chemotaxis to EGF. The genes in the invasion signature 
fall into coordinately regulated pathways that suggest that 
these tumor cells can communicate with and follow macro-
phages during invasion (Condeelis et al., 2005). Based on 
this signature, a tumor microenvironment invasion model 
has been proposed in which tumorigenesis leads to the 
development of microenvironments within the tumor, which 
presumably result from the stable gene-expression patterns 
seen by whole-tumor profiling. These stable expression pat-
terns might lead, for example, to increased inflammation 
and macrophage involvement in tumor progression and to 
the invasion microenvironment, which in turn would elicit 
transient gene-expression patterns in tumor cells that sup-
port invasion (similar to the way in which transient patterns 
of gene expression support the invasion of the fat pad by 
mammary ductal epithelial cells during normal development) 
(Figure 1). An interesting prediction of the tumor microenvi-
ronment model is that the early and uniform expression of 
certain genes could lead to the random appearance, in time 
and location, of an invasion microenvironment. This would 
cause repeated episodes of invasion and micrometastasis 
that increase in frequency as the tumor progresses but that 
are not necessarily limited to late stage carcinomas (Wang 
et al., 2005 and references within).
Angiogenesis
Clinical evidence shows a correlation between local 
macrophage density and areas of intense angiogenesis 
defined by the presence of microvessels, suggesting a 
role for macrophages in this process (Leek and Harris, 
2002). In the polyoma middle T oncoprotein model for 
mammary cancer, depletion of macrophages inhibits the 
Figure 3. Macrophages Play a Direct Role in the 
Invasion and Intravasation of Mammary Tumor Cells
Macrophages are involved in a paracrine loop with tumor cells dur-
ing the initial stages of metastasis. Carcinoma cells of metastatic 
tumors exhibit high-velocity polarized movement along collagen 
fibers toward blood vessels as a result of chemotaxis. Chemo-
taxis to the blood vessel occurs in response to chemoattractants 
such as EGF secreted by macrophages associated with the ves-
sels. Cancer cells express the EGF receptor (EGFR) and secrete 
CSF-1, which attracts macrophages and induces 
them to express EGF, thereby completing the 
paracrine loop. Collagen-containing fibers sup-
port tumor-associated vessels like a spider web 
with the vessel at the center. The convergence of 
these fibers on vessels has the effect of directing 
macrophage-induced tumor cell movement to the 
vessels. (Adapted from Lin et al., 2002; Condee-
lis and Segall, 2003.) Inset: signaling between the 
macrophage and the tumor cell affects the activity 
of actin regulators such as WASP and N-WASP, 
resulting in the formation of podosomes in macro-
phages and invadopodia in tumor cells to promote 
tumor cell intravasation.
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angiogenic switch that occurs during the malignant transi-
tion and the subsequent remodeling of the vasculature as 
the tumors become late carcinomas (E.Y. Lin and J.W.P., 
unpublished data). Tumor-derived signals appear to recruit 
a subset of monocytes that express a marker normally 
restricted to endothelial cells, Tie2, and that are respon-
sible for neoangiogenesis. The ablation of this specialized 
cell type remarkably reduced angiogenesis in the tumor 
and caused its regression (De Palma et al., 2005). Signals 
for this macrophage recruitment include hypoxia caused 
by the tumor’s outgrowing the vascular supply (Murdoch 
et al., 2004). Hypoxia induces the HIF transcription fac-
tors in these cells whose targets include genes for many 
angiogenic factors, such as VEGF, whose action enhances 
angiogenesis in these avascular areas. Indeed, in a mouse 
model for cervical cancer, inhibition of the matrix metal-
loproteinase MMP9 in macrophages blocked the release 
of VEGF and thereby inhibited angiogenesis and tumor 
growth (Giraudo et al., 2004). These data strongly suggest 
that macrophages play a role in both initiation of angiogen-
esis in avascular areas and in the remodeling of the vascu-
lature once formed to give coherent vascular flow. Indeed, 
similar functions of macrophages appear to be used in 
wound healing and during the remodeling of the vascula-
ture in the eye during postnatal development (Lobov et al., 
2005), coupling pathological angiogenesis in tumors with 
the normal physiological role of macrophages.
Thus, macrophages not only increase vascularization to 
provide sustenance to the tumor but also promote metasta-
sis by enhancing tumor cell movement toward and intravasa-
tion into an increased number of vessels. This places mac-
rophages at the center of an invasion microenvironment.
Seeding at Distant Sites
The events that occur at distant sites are similar to those 
at the primary tumor. Circulating tumor cells, in either the 
lymphatic or blood system, are believed to exit vessels 
(extravasate) to establish a proliferative niche where angio-
genesis is necessary for sustained growth. There is evi-
dence that suggests that macrophages play an important 
role during these processes, including clinical observations 
that the number of macrophages associated with metas-
tases in the lymph nodes correlates well with poor survival 
(Oberg et al., 2002). Primary tumors induce the expres-
sion of MMP9 in macrophages at sites of lung metastasis, 
thereby causing the release of bound VEGF, which pro-
motes angiogenesis (Pollard, 2004 and references within). 
Furthermore, depletion of macrophages in the peritoneum 
reduced the ability of carcinoma cells introduced into the 
portal vein to seed and grow in the lung (Oosterling et al., 
2005). Although these data showing that macrophages 
promote metastatic lesions are still scant, they are con-
sistent with the poor capacity for metastasis of mammary 
tumors in macrophage-depleted mice (Lin et al., 2001).
Conclusion
The trophic activities of macrophages may play a causative 
role in defining the invasion microenvironment of mammary 
and other types of tumors. Macrophages do not harbor 
malignant mutations and therefore have a stable genome; 
they thus are much less likely to develop drug resistance. 
This makes them a good target for cytostatic treatment 
of tumor progression to malignancy using small molecule 
inhibitors of selected macrophage functions. Studying the 
signaling pathways that allow macrophages to contribute to 
tumor progression will lead to new insights into the evolution 
of the microenvironments supporting invasion and metas-
tasis, thereby providing targets for anticancer therapies.
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